Powered by

Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5 Topical Hemostat

Aug 06, 2019 - ICT Monitor Worldwide

(GlobeNewswire) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, announced today the results of two studies supporting the underlying antimicrobial properties of the Companys AC5TM self-assembling peptide technology platform (AC5). Arch also provided an update on the status of the CE Marking process for AC5TM Topical Hemostat in the European Union.

The first study used an in vitro bioburden model ...